On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl ester derivative tested on an epidermal equivalent of human skin

Photochemistry and Photobiology

Volumn 82, Issue 4, 2006, Pages 1069-1076

  Uehlinger, Pascal ^a   Ballini, Jean Pierre ^a   Van Den Bergh, Hubert ^a   Wagnières, Georges ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; CHELATING AGENT; DRUG DERIVATIVE; ESTER; IRON; PROTOPORPHYRIN;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG EFFECT; EPIDERMIS; HUMAN; METABOLISM; SKIN;

AMINOLEVULINIC ACID; CELLS, CULTURED; CHELATING AGENTS; EPIDERMIS; ESTERS; HUMANS; IRON; PROTOPORPHYRINS; SKIN;

EID: 33749022248     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/2005-12-04-RA-745     Document Type: Article

References (69)

1. Zeitouni, N. C., A. R. Oseroff and S. Shieh (2003) Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol. Immunol. 39, 1133-1136.
2. Morton, C. A. (2002) The emerging role of 5-ALA-PDT in dermatology: Is PDT superior to standard treatments? J. Dermatol. Treat. 13 (Suppl. 1), S25-29.
3. Taub, A. F. (2004) Photodynamic therapy in dermatology: History and horizons. J. Drugs Dermatol. 3 (1 Suppl.), S8-25.
4. Kennedy, J. C., R. H. Pettier and D. C. Pross (1990) Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B Biol. 6, 143-148.
5. Tishler, P. V. (1999) The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria. Life Sci. 65, 207-214.
6. Kondo, M., N. Hirota, T. Takaoka and M. Kajiwara (1993) Hemebiosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat. Cell Biol. Toxicol. 9, 95-105.
7. Lecerof, D., M. Fodje, A. Hansson, M. Hansson and S. Al Karadaghi (2000) Structural and mechanistic basis of porphyrin metallation by ferrochelatase. J. Mol. Biol. 297, 221-232.
8. Bhasin, G., H. Kausar and M. Athar (1999) Ferrochelatase, a novel target for photodynamic therapy of cancer. Oncol. Rep. 6, 1439-1442.
9. Hinnen, P., F. W. de Rooij, M. L. van Velthuysen, A. Edixhoven, R. van Hillegersberg, H. W. Tilanus, J. H. Wilson and P. D. Siersema (1998) Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus. Br. J. Cancer 78, 679-682.
10. Kennedy, J. C. and R. H. Pettier (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol. B Biol. 14, 275-292.
11. Jichlinski, P., L. Guillou, S. J. Karlsen, P. U. Malmstrom, D. Jocham, B. Brennhovd, E. Johansson, T. Gatner, N. Lange, H. van den Bergh and H. J. Leisinger (2003) Hexyl aminolevulinate fluorescence cystoscopy: New diagnostic tool for photodiagnosis of superficial bladder cancer - A multicenter study. J. Urol. 170, 226-229.
12. Donnelly, R. F., P. A. McCarron and A. D. Woolfson (2005) Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem. Photobiol. 81, 750-767.
13. Clark, C., A. Bryden, R. Dawe, H. Moseley, J. Ferguson and S. H. Ibbotson (2003) Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol. Photoimmunol. Photomed. 19, 134-141.
14. Taylor, E. L. and S. B. Brown (2002) The advantages of aminolevulinic acid photodynamic therapy in dermatology. J. Dermatol. Treat. 13 (Suppl. 1), S3-11.
15. Jeffes, E. W. (2002) Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J. Dermatol. Treat. 13(Suppl. 1), S19-23.
16. Morton, C. A. (2003) Methyl aminolevulinate (Metvix) photodynamic therapy - Practical pearls. J Dermatol. Treat. 14 (Suppl. 3), 23-26.
17. Casas, A., C. Perotti, H. Fukuda, L. Rogers, A. R. Butler and A. Batlle (2001) ALA and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tumours: The role of different vehicles on improving photosensitization. Br. J. Cancer 85, 1794-1800.
18. Gahlen, J., J. Stern, J. Pressmar, J. Bohm, R. Holle and C. Herfarth (2000) Local 5-aminolevulinic acid application for laser light-induced fluorescence diagnosis of early staged colon cancer in rats. Lasers Surg. Med. 26, 302-307.
19. Gerscher, S., J. P. Connelly, J. Griffiths, S. B. Brown, A. J. MacRobert, G. Wong and L. E. Rhodes (2000) Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem. Photobiol. 72, 569-574.
20. Collaud, S., N. Lange, A. Juzeniene and J. Moan (2004) On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr. Med. Chem. Anti-Cancer Agents 4, 301-316.
21. Fritsch, C., B. Homey, W. Stahl, P. Lehmann, T. Ruzicka and H. Sies (1998) Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem. Photobiol. 68, 218-221.
22. Peng, Q., T. Warloe, J. Moan, H. Heyerdahl, H. B. Steen, J. M. Nesland and K. E. Giercksky (1995) Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem. Photobiol. 62, 906-913.
23. Martin, A., W. D. Tope, J. M. Grevelink, J. C. Starr, J. L. Fewkes, T. J. Flotte, T. F. Deutsch and R. R. Anderson (1995) Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch. Dermatol. Res. 287, 665-674.
24. de Blois, A. W., M. R. Thissen, H. S. de Bruijn, R. J. Grouls, R. P. Dutrieux, D. J. Robinson and H. A. Neumann (2001) In vivo pharmacokinetics of protoporphyrin IX accumulation following intracutaneous injection of 5-aminolevulinic acid. J. Photochem. Photobiol. B Biol. 61, 21-29.
25. af Klinteberg, C., A. M. Enejder, I. Wang, S. Andersson Engels, S. Svanberg and K. Svanberg (1999) Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas. J. Photochem. Photobiol. B Biol. 49, 120-128.
26. Ninomiya, Y., Y. Itoh, S. Tajima and A. Ishibashi (2001) In vitro and in vivo expression of protoporphyrin IX induced by lipophilic 5-aminolevulinic acid derivatives. J. Dermatol. Sci. 27, 114-120.
27. Kristiansson, S., A. Juzeniene, P. Juzenas, V. Iani, L. Löfgren and J. Moan (2005) Kinetics of protoporphyrin IX formation in rat oral mucosa and skin after application of 5-aminolevulinic acid and its methylester. Photochem. Photobiol. 81, 394-397.
28. Malik, E., A. Meyhofer-Malik, D. Trutenau, H. Diddens, W. Kupker and K. Diedrich (1998) Photodynamic diagnosis of endometriosis using 5-aminolevulinic acid - A pilot study. Geburtshilfe und Frauenheilkunde 58, 420-425. [In German]
29. De Rosa, F. S., J. M. Marchetti, J. A. Thomazini, A. C. Tedesco and M. V. Bentley (2000) A vehicle for photodynamic therapy of skin cancer: Influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J. Control. Release 65, 359-366.
30. Pourzand, C., O. Reelfs, E. Kvam and R. M. Tyrrell (1999) The iron regulatory protein can determine the effectiveness of 5-aminolevulinic acid in inducing protoporphyrin IX in human primary skin fibroblasts. J. Investig. Dermatol. 112, 419-425.
31. Fijan, S., H. Honigsmann and B. Ortel (1995) Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br. J. Dermatol. 133, 282-288.
32. Choudry, K., R. C. Brooke, W. Farrar and L. E. Rhodes (2003) The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br. J. Dermatol. 149, 124-130.
33. Berg, K., H. Anholt, O. Bech and J. Moan (1996) The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br. J. Cancer 74, 688-697.
34. van den Akker, J. T., K. Boot, D. I. Vernon, S. B. Brown, L. Groenendijk, G. C. van Rhoon and H. J. Sterenborg (2004) Effect of elevating the skin temperature during topical ALA application on in vitro ALA penetration through mouse skin and in vivo PpIX production in human skin. Photochem. Photobiol. Sci. 3, 263-267.
35. Juzeniene, A., P. Juzenas, O. Kaalhus, V. Iani and J. Moan (2002) Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem. Photobiol. 76, 452-456.
36. Robinson, D. J., H. S. de Bruijn, W. M. Star and H. J. Sterenborg (2003) Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem. Photobiol. 77, 319-323.
37. Dögnitz, N., D. Salomon, J.-P. Ballini, T. Gabrecht, N. Lange, H. van den Bergh and G. Wagnieres (2004) Comparison of ALA and ALA hexyl-ester induced PPIX depth distribution in human skin carcinoma. J. Investig. Dermatol. (Submitted)
38. Uehlinger, P., M. Zellweger, G. Wagnieres, L. Juillerat Jeanneret, H. van den Bergh and N. Lange (2000) 5 Aminolevulinic acid and its derivatives: Physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B Biol. 54, 72-80.
39. Peng, Q., J. Moan, T. Warloe, V. Iani, H. B. Steen, A. Bjorseth and J. M. Nesland (1996) Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J. Photochem. Photobiol. B Biol. 34, 95-96.
40. De Rosa, F. S., A. C. Tedesco, R. F. Lopez, M. B. Riemma Pierre, N. Lange, J. M. Marchetti, J. C. Gomes Rotta and M. V. Lopes Badra Bentley (2003) In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J. Control. Release 89, 261-269.
41. Wulf, H. C. and P. Philipsen (2004) Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy. Br. J. Dermatol. 150, 143-145.
42. Kloek, J. and H. Beijersbergen van (1996) Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem. Photobiol. 64, 994-1000.
43. Limat, A., D. Mauri and T. Hunziker (1996) Successful treatment of chronic leg ulcers with epidermal equivalents generated from cultured autologous outer root sheath cells. J. Invest. Dermatol. 107, 128-135.
44. Tausche. A. K., M. Skaria, L. Bohlen, K. Liebold, J. Hafner, H. Friedlein, M. Meurer, R. J. Goedkoop, U. Wollina, D. Salomon and T. Hunziker (2003) An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair. Regen. 11, 248-252.
45. Dietel, W., C. Fritsch, R. Pottier and R. Wendenburg (1997) 5-Aminolaevulinic-acid-induced formation of different porphyrins and their photomoditications. Lasers Med. Sci. 12, 226-236.
46. Rotomskis, R., S. Bagdonas, G. Streckyte, R. Wendenburg, W. Dietel, J. Didziapetriene, A. Ibelhauptaite and L. Staciokiene (1998) Phototransformation of sensitizers: 3. Implications for clinical dosimetry. Lasers Med. Sci. 13, 271-278.
47. Bagdonas, Q., L. W. Ma, V. Iani, R. Rotomskis, P. Juzenas, and J. Moan (2000) Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: A spectroscopic study. Photochem. Photobiol. 72, 186-192.
48. Finlay, J. C., D. L. Conover, E. L. Hull and T. H. Foster (2001) Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo. Photochem. Photobiol. 73, 54-63.
49. Iinuma, S., K. T. Schomacker, G. Wagnieres, M. Rajadhyaksha, M. Bamberg, T. Momma and T. Hasan (1999) In vivo fluence rate and fractionation effects on tumor response and photobleaching: Photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res. 59, 6164-6170.
50. Mesenholler, M. and E. K. Matthews (2000) A key role for the mitochondrial benzodiazepine receptor in cellular photosensitisation with delta-aminolaevulinic acid. Eur. J. Pharmacol. 406, 171-180.
51. Jacobs, J. M., P. R. Sinclair, J. F. Sinclair, N. Gorman, H. S. Walton, S. G. Wood and C. Nichols (1998) Formation of zinc protoporphyrin in cultured hepatocytes: Effects of ferrochelatase inhibition, iron chelalion or lead. Toxicology 125, 95-105.
52. Bloomer, J. R., R. J. Reuter, K. O. Morton and J. M. Wehner (1983) Enzymatic formation of zinc-protoporphyrin by rat liver and its potential effect on hepatic heme metabolism. Gastroenterology 85, 663-668.
53. Nelson, J. C., M. Westwood, K. R. Allen, K. E. Newton and J. H. Barth (1998) The ratio of erythrocyte zinc-protoporphyrin to protoporphyrin IX in disease and its significance in the mechanism of lead toxicity on haem synthesis. Ann. Clin. Biochem. 35, 422-426.
54. Perotti, C., H. Fukuda, G. Di Venosa, A. MacRobert, A. Batlle and A. Casas (2004) Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies. Br. J. Cancer 90, 1660-1665.
55. Tsai, J. C., I. H. Chen, T. W. Wong and Y. L. Lo (2002) In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation. Br. J. Dermatol. 146, 853-862.
56. Limat, A., D. Salomon, P. Carraux, J. H. Saurat and T. Hunziker (1999) Human melanocytes grown in epidermal equivalents transfer their melanin to follicular outer root sheath keratinocytes. Arch. Dermatol. Res. 291, 325-332.
57. Fritsch, C., P. Lehmann, W. Stahl, K. W. Schulte, E. Blohm, K. Lang, H. Sies and T. Ruzicka (1999) Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br. J. Cancer 79, 1603-1608.
58. Stringer, M. R., P. Collins, D. J. Robinson, G. I. Stables and R. A. Sheehan Dare (1996) The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J. Investig. Dermatol. 107, 76-81.
59. Lange, N., P. Jichlinski, M. Zellweger, M. Forrer, L. Guillou, P. Kucera, G. Wagnières and H. van den Bergh (1999) Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: A pilot study. Br. J. Cancer 80, 185-193.
60. Casas, A., A. M. Batlle, A. R. Butler, D. Robertson, E. H. Brown, A. MacRobert and P. A. Riley (1999) Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br. J. Cancer 80, 1525-1532.
61. Wu, S. M., Q. G. Ren, M. O. Zhou, Y. Wei, and J. Y. Chen (2003) Photodynamic effects of 5-aminolevulinic acid and its hexylester on several cell lines. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35, 655-660.
62. Collins, P., D. J. Robinson, M. R. Stringer, G. I. Stables and R. A. Sheehan Dare (1997) The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br. J. Dermatol. 137, 743-749.
63. Peng, Q., K. Berg, J. Moan, M. Kongshaug and J. M. Nesland (1997) 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research. Photochem. Photobiol. 65, 235-251.
64. Richardson, D. R. (2002) Therapeutic potential of iron chelators in cancer therapy. Adv. Exp. Med. Biol. 509, 231-249.
65. Britton, R. S., K. L. Leicester and B. R. Bacon (2002) Iron toxicity and chelation therapy. Int. J. Hematol. 76, 219-228.
66. Barboy, N. and J. Feitelson (1987) Quenching of the zinc-protoporphyrin triplet state as a measure of small-molecule diffusion through the structure of myoglobin. Biochemistry 26, 3240-3244.
67. Feitelson, J. and N. Barboy (1986) Triplet-state reactions of Zinc-protoporphyrins. J. Phys. Chem. 90, 271.
68. Stepinac, T., S. Chamot, E. Rungger, P. Ferrez, J. L. Munoz, H. van den Bergh, C. J. Pournaras, C. Riva and G. Wagnieres (2005) Light-induced retinal vascular damage by Pd-porphyrin luminescent oxygen probes. Invest. Ophthalmol. Vis. Sci. 46, 956-966.
69. Licato, L. L., V. G. Prieto and E. A. Grimm (2001) A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels. In Vitro Cell. Dev. Biol. Anim. 37, 121-126.